Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
University of Utah Research v. Ambry Genetics Corporation
Case Number:
14-1361
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
December 17, 2014
Many Biotech Patents At Risk After Fed. Circ. Myriad Ruling
By striking down Myriad Genetics Inc. breast cancer test patents Wednesday, the Federal Circuit greatly expanded the reach of a U.S. Supreme Court decision on Myriad's patents on human genes and has thrown into question the validity of scores of patents involving natural material, attorneys say.
-
December 17, 2014
Fed. Circ. Strikes Down More Myriad Cancer Test Patents
The Federal Circuit ruled Wednesday that three Myriad Genetics Inc. breast cancer test patents are invalid for claiming patent-ineligible subject matter, another major setback for the company after the U.S. Supreme Court ruled last year that it could not patent human genes.
-
October 03, 2014
Fed. Circ. To Eye Gene Patent Ruling's Reach In Myriad Case
The Federal Circuit will hear arguments Monday in a case that may clarify whether the U.S. Supreme Court's decision that Myriad Genetics Inc. cannot patent human genes invalidates other inventions involving natural products, as Myriad appeals the denial of an injunction in a case over its cancer-testing patents.
-
June 11, 2014
ACLU Fights Myriad's Bid For Cancer-Test Sales Ban
The American Civil Liberties Union and other groups that successfully invalidated Myriad Genetics Inc.'s isolated DNA patents in a U.S. Supreme Court case last year, urged the Federal Circuit on Monday to reject Myriad's bid to ban sales of cancer tests based on different patents.
-
April 23, 2014
Myriad Asks Fed. Circ. To Block Ambry Cancer Test In IP Row
Myriad Genetics Inc. on Friday asked the Federal Circuit to revive its bid for an injunction on Ambry Genetics Corp.'s cancer-testing products, arguing the lower court judge incorrectly held that Myriad's patents were likely invalid for claiming patent-ineligible subject matter.
-
April 14, 2014
Myriad Loses Fed. Circ. Bid For Quick Cancer Test Appeal
Myriad Genetics Inc.'s fight to block the sales of Ambry Genetics Corp.'s cancer-testing products and defend a slew of its patents that were at the center of a high-profile U.S. Supreme Court ruling last year will have to wait its turn, the Federal Circuit ruled Monday.